)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Shanghai RAAS Blood Products
Shanghai RAAS Blood Products (002252) investor relations material
Shanghai RAAS Blood Products Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary27 Oct, 2026
Executive summary
Q3 revenue was RMB 1.735bn and adjusted net profit attributable to shareholders was RMB 321.5m; both were annual lows? No: both reached year-to-date highs, while declining YoY.
Management cited sequential improvement, with revenue rising for a second consecutive quarter and adjusted net profit growing QoQ; Q3 revenue and adjusted net profit were both 2026 highs.
Strategy centers on plasma collection and innovation-drug development, supported by Haier’s healthcare ecosystem and a planned shift toward an integrated biologics platform.
Financial highlights
Q3 revenue RMB 1.735bn, down 18.90% YoY; 9M revenue RMB 4.944bn, down 18.83%.
Q3 attributable net income RMB 317.7m, down 27.93%; 9M attributable net income RMB 978.9m, down 33.44%.
Adjusted for non-recurring items, Q3 attributable net income was RMB 321.5m, down 27.74%; 9M was RMB 947.2m, down 36.22%.
Q3 basic and diluted EPS were RMB 0.048, each down 28.36% YoY; 9M EPS was RMB 0.148, down 33.33%.
Outlook and guidance
Q4 priorities: accelerate target-hospital access, prepare for centralized procurement implementation, coordinate shipments, optimize inventory, strengthen operating foundations, and advance clinical and industrialization plans.
Longer-term priorities include sustaining R&D investment, expanding indications, accelerating innovative-drug launches, and building an AI-enabled biologics platform.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Shanghai RAAS Blood Products
- Revenue and profit fell, but R&D, innovation, and global expansion drive future growth.002252
Q2 2026 - Q1 2026 saw revenue and profit decline sharply year-over-year, but sequential improvement emerged.002252Q1 2026
- Revenue and profit declined, but plasma expansion and innovation drive future growth.002252Q4 2025
- Net profit dropped 26% on flat revenue, with major buybacks and clinical trial advances.002252Q3 2025
- Revenue and profit fell, but cash flow and strategic expansion strengthened future prospects.002252Q2 2025
- Revenue and profit rose in Q3 2024 as Haier Group took control and R&D advanced.002252Q3 2024
- H1 2024 revenue up 9.02% YoY, Haier Group now controls Shanghai RAAS.002252Q2 2024
- 2024 saw robust profit growth, Haier control, and strategic expansion for Shanghai RAAS.002252Q4 2024
- Net profit fell 25% in Q1 2025, but strategic acquisitions and buybacks support future growth.002252Q1 2025
Next Shanghai RAAS Blood Products earnings date
Q4 202623 Apr, 2027
Shanghai RAAS Blood Products
Next Shanghai RAAS Blood Products earnings date
Q4 202623 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Shanghai RAAS Blood Products Co., Ltd. is a Chinese healthcare company focused on the research, development, production, and distribution of plasma-derived biopharmaceutical products. The company produces a variety of blood plasma-based therapies, including immunoglobulins, albumin, and coagulation factor products, used in the treatment of immune deficiencies, blood disorders, and other medical conditions. The company is headquartered in Shanghai, China, and its shares are listed on the Shenzhen Stock Exchange.